186 related articles for article (PubMed ID: 31603482)
1. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.
Jiao K; Gupta R; Fox E; Kesselheim A; Ross JS
JAMA Netw Open; 2019 Oct; 2(10):e1913029. PubMed ID: 31603482
[TBL] [Abstract][Full Text] [Related]
2. Generic Drug Approvals Since the 1984 Hatch-Waxman Act.
Gupta R; Kesselheim AS; Downing N; Greene J; Ross JS
JAMA Intern Med; 2016 Sep; 176(9):1391-3. PubMed ID: 27428055
[No Abstract] [Full Text] [Related]
3. FDA posts record number of drug approvals in 1996.
Am J Health Syst Pharm; 1997 Mar; 54(5):494, 497-8. PubMed ID: 9066856
[No Abstract] [Full Text] [Related]
4. Changes in the Number of Continuation Patents on Drugs Approved by the FDA.
Tu SS; Kesselheim AS; Wetherbee K; Feldman WB
JAMA; 2023 Aug; 330(5):469-470. PubMed ID: 37526728
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Outcomes of Products Seeking Competitive Generic Therapy Designation and Exclusivity.
Chahal HS; Fowler AC; Patel R; Shimer M
JAMA; 2021 Nov; 326(18):1863-1865. PubMed ID: 34751720
[TBL] [Abstract][Full Text] [Related]
6. An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018.
Lanthier ML; Kerr KW; Miller KL
Clin Pharmacol Ther; 2019 Nov; 106(5):1125-1132. PubMed ID: 31206617
[TBL] [Abstract][Full Text] [Related]
7. What's the problem with generic antiepileptic drugs?: a call to action.
Berg MJ
Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
[No Abstract] [Full Text] [Related]
8. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
Eckert JC
Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
[TBL] [Abstract][Full Text] [Related]
9. Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.
Lythgoe MP; Middleton P
JAMA Netw Open; 2021 Jun; 4(6):e2114531. PubMed ID: 34170306
[TBL] [Abstract][Full Text] [Related]
10. Priority drugs well represented among 1998 approvals. FDA says all performance goals were met.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):408, 411-2. PubMed ID: 10096697
[No Abstract] [Full Text] [Related]
11. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
12. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
13. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.
Nair AK; Anand O; Chun N; Conner DP; Mehta MU; Nhu DT; Polli JE; Yu LX; Davit BM
AAPS J; 2012 Dec; 14(4):664-6. PubMed ID: 22718306
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
[TBL] [Abstract][Full Text] [Related]
15. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
16. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
Feldman R; Wang C
N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
[No Abstract] [Full Text] [Related]
17. Updated trends in US brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R; Boyo A
J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
[TBL] [Abstract][Full Text] [Related]
18. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
19. Countering delays in introduction of generic drugs.
Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
[No Abstract] [Full Text] [Related]
20. New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs.
Rajasingham R; Boulware DR
Clin Infect Dis; 2019 Aug; 69(4):732. PubMed ID: 30698690
[No Abstract] [Full Text] [Related]
[Next] [New Search]
